Palisade Bio Reports $132.6M Cash to Fund Phase 2 UC and CD Trials
Palisade Bio ended Q1 with $132.6M cash after R&D spending rose to $6.4M and G&A to $4.4M, funding through planned Phase 2 UC (H2 2027) and CD (early 2028) readouts. Phase 1b fibrostenotic Crohn’s cohort showed PALI-2108 exposure above IC90 in colon tissue with inflammatory and fibrotic pathway modulation and favorable safety.
1. Q1 2026 Financial Results
Research and development expenses increased to $6.4 million for the quarter ended March 31, 2026, up from $1.0 million a year earlier, while general and administrative costs rose to $4.4 million from $1.4 million. Cash and cash equivalents totaled $132.6 million as of March 31, positioning the company to fund operations through key Phase 2 efficacy readouts in ulcerative colitis and Crohn’s disease.
2. Clinical Progress of PALI-2108
The Phase 1b fibrostenotic Crohn’s disease cohort for PALI-2108 demonstrated sustained active metabolite exposure above IC90 thresholds in colon tissue, modulation of inflammatory and fibrotic pathways, and a favorable safety and tolerability profile. These results complement earlier Phase 1a/b ulcerative colitis data showing target engagement in ileal and colonic tissues.
3. Upcoming Milestones and Cash Runway
Palisade plans IND submissions for its Phase 2 ulcerative colitis trial in Q2 2026 and for its Crohn’s disease trial in H2 2026, with trial starts targeted for Q3 2026 and Q1 2027, respectively. Primary efficacy readouts are expected in the second half of 2027 for UC and in early 2028 for CD.